VCG
AMPH icon

Vantage Consulting Group’s Amphastar Pharmaceuticals AMPH Stock Holding History

Vantage Consulting Group’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,532
Closed -$71K – 181
2020
Q4 		$71K Buy
+3,532
New +$68.7K 0.01% 309

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Vantage Consulting Group's AMPH Position: Q1 2021 in Review

Vantage Consulting Group sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2021, closing a stake of 3,532 shares — an estimated $71K sold.

Vantage Consulting Group first reported a position in AMPH in Q4 2020 and held it in 1 quarter. The position peaked at $71K in Q4 2020. 135 funds tracked by Wall St. Rank hold AMPH as of Q1 2021.

  • Vantage Consulting Group reported no remaining Amphastar Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 3,532 Amphastar Pharmaceuticals shares in Q1 2021, an estimated $71K.
  • Vantage Consulting Group first reported a position in Amphastar Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's Amphastar Pharmaceuticals position peaked at $71K in Q4 2020.
  • 135 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.